NO20014841L - Anti-HIV-1 vaksine som omfatter hele eller del av HIV-1 TAT proteinet - Google Patents

Anti-HIV-1 vaksine som omfatter hele eller del av HIV-1 TAT proteinet

Info

Publication number
NO20014841L
NO20014841L NO20014841A NO20014841A NO20014841L NO 20014841 L NO20014841 L NO 20014841L NO 20014841 A NO20014841 A NO 20014841A NO 20014841 A NO20014841 A NO 20014841A NO 20014841 L NO20014841 L NO 20014841L
Authority
NO
Norway
Prior art keywords
hiv
vaccine
protein
tat protein
tat
Prior art date
Application number
NO20014841A
Other languages
English (en)
Other versions
NO326603B1 (no
NO20014841D0 (no
Inventor
Erwann Loret
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9904610A external-priority patent/FR2792204B1/fr
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of NO20014841D0 publication Critical patent/NO20014841D0/no
Publication of NO20014841L publication Critical patent/NO20014841L/no
Publication of NO326603B1 publication Critical patent/NO326603B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet en oppfinnelse som angår en anti-HIV-1 - vaksine som omfatter hele eller delen av Tat HIV-1-proteinet, i tillegg til identifikasjon av nevnte protein hos individer affisert av HIV. Tat-proteinet er et protein av HIV-1 Oyi-varianten.
NO20014841A 1999-04-13 2001-10-04 Anti-HIV-1 vaksine som omfatter et HIV-1 TAT Oyi protein eller ekspressjonsvektor omfattende nukleotidsekvens som koder for variantproteinet og fremgangsmate for fremstilling av anti-Tat polyklonale antistoffer og fremstilling av Tat-varianten NO326603B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9904610A FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
FR9916633A FR2792206B1 (fr) 1999-04-13 1999-12-29 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
PCT/FR2000/000938 WO2000061067A2 (fr) 1999-04-13 2000-04-12 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1

Publications (3)

Publication Number Publication Date
NO20014841D0 NO20014841D0 (no) 2001-10-04
NO20014841L true NO20014841L (no) 2001-11-27
NO326603B1 NO326603B1 (no) 2009-01-19

Family

ID=26234914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014841A NO326603B1 (no) 1999-04-13 2001-10-04 Anti-HIV-1 vaksine som omfatter et HIV-1 TAT Oyi protein eller ekspressjonsvektor omfattende nukleotidsekvens som koder for variantproteinet og fremgangsmate for fremstilling av anti-Tat polyklonale antistoffer og fremstilling av Tat-varianten

Country Status (20)

Country Link
US (1) US7087377B2 (no)
EP (1) EP1169057B1 (no)
JP (1) JP4860823B2 (no)
KR (1) KR100725637B1 (no)
AT (1) ATE280586T1 (no)
AU (1) AU775560B2 (no)
BR (1) BR0009758A (no)
CA (1) CA2370563C (no)
DE (1) DE60015312T2 (no)
DK (1) DK1169057T3 (no)
ES (1) ES2231178T3 (no)
FR (1) FR2792206B1 (no)
HK (1) HK1044463B (no)
HU (1) HUP0200841A2 (no)
IL (2) IL145884A0 (no)
MX (1) MXPA01010482A (no)
NO (1) NO326603B1 (no)
PL (1) PL197666B1 (no)
PT (1) PT1169057E (no)
WO (1) WO2000061067A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100465589B1 (ko) * 2001-04-20 2005-01-13 허만욱 비만 억제 폴리펩타이드
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
WO2009130256A2 (en) * 2008-04-22 2009-10-29 Universite De La Mediterranee Compositions and methods for preventing or treating aids
NZ595060A (en) * 2009-03-23 2013-05-31 Pin Pharma Inc Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2011128720A1 (en) * 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
DK2928910T3 (da) 2012-12-06 2019-10-07 Pin Pharma Inc Behandling af inflammation, autoimmune og neurodegenerative sygdomme med immunosuppressive tat-derivat polypeptider
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
JP2016533352A (ja) 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド 免疫刺激性ＨＩＶ Ｔａｔ誘導体ポリペプチドによる癌の治療
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5019510A (en) 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
PL322143A1 (en) * 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
DE19514089C2 (de) * 1995-04-13 1997-07-10 Deutsches Krebsforsch Nachweisverfahren für HIV-TAT
JPH10212300A (ja) * 1996-11-26 1998-08-11 Sankyo Co Ltd ペプチドワクチン
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
DE60015312T2 (de) 2006-02-09
ATE280586T1 (de) 2004-11-15
ES2231178T3 (es) 2005-05-16
EP1169057A2 (fr) 2002-01-09
FR2792206B1 (fr) 2006-08-04
WO2000061067A2 (fr) 2000-10-19
DK1169057T3 (da) 2005-03-07
KR20020005675A (ko) 2002-01-17
NO326603B1 (no) 2009-01-19
AU775560B2 (en) 2004-08-05
HUP0200841A2 (en) 2002-07-29
HK1044463B (zh) 2005-06-03
CA2370563C (fr) 2013-12-17
CA2370563A1 (fr) 2000-10-19
MXPA01010482A (es) 2002-09-18
HK1044463A1 (en) 2002-10-25
WO2000061067A3 (fr) 2001-03-29
US7087377B2 (en) 2006-08-08
DE60015312D1 (de) 2004-12-02
PL353033A1 (en) 2003-10-06
PT1169057E (pt) 2005-03-31
EP1169057B1 (fr) 2004-10-27
FR2792206A1 (fr) 2000-10-20
AU3972400A (en) 2000-11-14
PL197666B1 (pl) 2008-04-30
NO20014841D0 (no) 2001-10-04
KR100725637B1 (en) 2007-06-07
WO2000061067B1 (fr) 2001-05-10
IL145884A (en) 2007-09-20
JP4860823B2 (ja) 2012-01-25
US20050106161A1 (en) 2005-05-19
JP2002541165A (ja) 2002-12-03
BR0009758A (pt) 2002-01-08
IL145884A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
NO20014841L (no) Anti-HIV-1 vaksine som omfatter hele eller del av HIV-1 TAT proteinet
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
HUP0204250A1 (hu) HIV-protein vagy- polinukleotid alkalmazása vakcina előállítására
DE60234018D1 (de) Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
DK0813542T3 (da) Aminosyrehydroxyethylaminosulfonamid som retrovirale proteaseinhibitorer
BR9607625A (pt) Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
EE9700200A (et) Bis-aminohappe hüdroksüetüülamino-sulfoonamiidsed retroviirusliku proteaasi inhibiitorid
BR0314657A (pt) Inibidores de fusão de derivados de peptìdeo de infecção de hiv
TR200102024T2 (tr) Yeni tedavi.
MX9700414A (es) Agentes antivirales de difluoroestatona.
MX9700044A (es) Combinacion triple anti-virus de inmunodeficiencia humana.
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ES2095899T3 (es) Peptidos de la proteina gag de vih, su preparacion y uso.
CY1105629T1 (el) Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv
FR2792204B1 (fr) Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem
ES2140329A1 (es) Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
AR009760A1 (es) El uso de proteinas como agentes anti-retrovirales
ECSP034800A (es) Derivados de pirazol

Legal Events

Date Code Title Description
MK1K Patent expired